CA NYSE

Valeant Pharmaceuticals International, Inc.

Specialty pharmaceutical roll-up that used undisclosed captive specialty pharmacy Philidor Rx Services to stuff channels and accelerate revenues.

CORPORATE IDENTIFIERS & DOSSIER
  • Entity Name: Valeant Pharmaceuticals International, Inc.
  • Country of Domicile: CA
  • Listing & Ticker: NYSE (VRX).
  • CIK / LEI Identifier: 0000885590.
  • Industry Classification: Pharmaceutical Preparations (SIC 2834).
  • Cumulative Overstatement: $58.0M across 1 enforcement episode(s).
  • Assessed Penalties: $45.0M.

PRIMARY ENFORCEMENT CASES INVOLVING VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

1 CASE DOSSIERS
Case Title Status Primary Scheme Overstatement Total Penalties Action Date
Valeant Pharmaceuticals: Undisclosed Captive Pharmacy Philidor and Channel Stuffing Settled, neither admitted nor denied channel stuffing $58.0M $45.0M September 20, 2017

FORENSIC PROFILE: VALEANT PHARMACEUTICALS: UNDISCLOSED CAPTIVE PHARMACY PHILIDOR AND CHANNEL STUFFING

FULL CASE DOSSIER →

Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels.

The company manipulated its accounting records by executing schemes under channel-stuffing. Financial reports filed with market regulators contained material misstatements that distorted true financial condition.

Fraud Window: January 1, 2015 to December 31, 2017 • Primary Regulator: U.S. Securities and Exchange Commission • Auditor: PricewaterhouseCoopers LLP

Documented Accounting Irregularities & Regulatory Findings

  • CHANNEL STUFFING: Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels.

Primary Public Dockets & Actions

  • [ENF-2015-valeant] Enforcement Action: Valeant Pharmaceuticals: Undisclosed Captive Pharmacy Philidor and Channel Stuffing (September 20, 2017): Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels. Official Record ↗